Vitamin D is an important regulator of the immune system, and it has been shown that deficiency of vitamin D is significant environmental factor in some immune-mediated diseases such as Multiple Sclerosis (MS). In this study, we have compared serum 25 hydroxyvitamin (OH) D levels in Relapsing-Remitting Multiple Sclerosis (RRMS), clinically isolated syndrome (CIS), and control groups.
Forty patients with CIS and 60 patients who have been diagnosed RRMS between age 18–45, respectively, and followed up at Pamukkale University Faculty of Medicine, Department of Neurology, and 60 healthy individuals have been included in this study. Serum 25(OH) vitamin D, calcium, phosphorus, alkaline phosphatase, parathormone, insulin, and fasting blood glucose levels were studied for all three groups.
A statistically significant difference was determined in the comparison of three groups for mean 25(OH) vitamin D levels. In the intergroup comparison of mean 25(OH) vitamin D; mean 25(OH) vitamin D level was determined to be statistically significantly lower in both RRMS and CIS groups compared to control group (p<0.05).
Since vitamin D deficiency poses a problem from the early stage of disease spectrum in both CIS patients and MS patients, 25(OH) vitamin D level should be routinely controlled, and replacement should be administered upon any deficiency state.
Funding source: Pamukkale University Scientific Research Projects Coordination Unit http://dx.doi.org/10.13039/501100004214
Award Identifier / Grant number: 2014TPF002
Research funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Pamukkale University Scientific Research Projects Coordination Unit (BAP) [2014TPF002].
Author contributions: AK designed the study, AK analyzed the data under supervision of LSB, ST processed data, SD and ST are the co-principal investigators, AK and ST reviewed LSB the literature and AK wrote the manuscript.
Competing interests: The authors declare that there is no conflict of interest.
Informed consent: All participants provided written informed consent before the study.
Ethical approval: The study was approved by the Pamukkale University Ethics Committee for non-interventional clinical research (27082013#12).
1. Munger, K, Levin, L, Hollis, B, Howard, N, Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832. https://doi.org/10.1001/jama.296.23.2832.Search in Google Scholar PubMed
2. Munger, K, Ascherio, A. Prevention and treatment of MS: studying the effects of vitamin D. Mult Scler J 2011;17:1405–11. https://doi.org/10.1177/1352458511425366.Search in Google Scholar PubMed PubMed Central
3. Smolders, J, Torkildsen, Ø, Camu, W, Hølmoy, T. An update on vitamin D and disease activity in multiple sclerosis. CNS Drugs 2019;33:1187–99. https://doi.org/10.1007/s40263-019-00674-8.Search in Google Scholar PubMed PubMed Central
4. Lucas, R, Ponsonby, A, Dear, K, Valery, P, Pender, M, Taylor, B, et al.. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011;76:540–8. https://doi.org/10.1212/wnl.0b013e31820af93d.Search in Google Scholar PubMed
5. Holick, MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009;19:73–8. https://doi.org/10.1016/j.annepidem.2007.12.001.Search in Google Scholar PubMed PubMed Central
6. Gökçen Tolgay, EN. Evaluation of serum vitamin D levels and its relation with neuropsychological tests during relapse and remission periods in relapsing remitting multiple sclerosis patients. Bursa, Turkey: Uludag University; 2011.Search in Google Scholar
7. Candan, FÜ. Evaluation of 25 hydroxycalciferol levels in multiple sclerosis patients with cranial magnetic resonance images. Istanbul: Bakırköy Prof. Dr. Mazhar Osman Research and Training Hospital for Psychiatric and Neurological Diseases; 2013.Search in Google Scholar
8. Mowry, E, Krupp, L, Milazzo, M, Chabas, D, Strober, J, Belman, A, et al.. Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann Neurol 2010;67:618–24. https://doi.org/10.1002/ana.21972.Search in Google Scholar PubMed
9. Martinelli, V, Costa, G, Colombo, B, Libera, D, Rubinacci, A, Filippi, M, et al.. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler J 2014;20:147–55. https://doi.org/10.1177/1352458513494959.Search in Google Scholar PubMed
10. Smolders, J, Menheere, P, Kessels, A, Damoiseaux, J, Hupperts, R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1220–4. https://doi.org/10.1177/1352458508094399.Search in Google Scholar PubMed
11. Van Der Mei, IAF, Ponsonby, AL, Dwyer, T, Blizzard, L, Taylor, BV, Kilpatrick, T, et al.. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007;254:581–90. https://doi.org/10.1007/s00415-006-0315-8.Search in Google Scholar PubMed
12. Runia, TF, Hop, WCH, Rijke, YB, Buljevac, D, Hintzen, RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012;79:261–6. https://doi.org/10.1212/wnl.0b013e31825fdec7.Search in Google Scholar
13. Simpson, S, Taylor, B, Blizzard, L, Ponsonby, AL, Pittas, F, Tremlett, H, et al.. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193–203. https://doi.org/10.1002/ana.22043.Search in Google Scholar
15. Ford, ES, Zhao, G, Tsai, J, Li, C. Associations between concentrations of vitamin D and concentrations of insulin, glucose, and HbA 1camong adolescents in the United States. Diabetes Care 2011;34:646–8. https://doi.org/10.2337/dc10-1754.Search in Google Scholar
16. Auer, DP, Schumann, EM, Kümpfel, T, Gössl, C, Trenkwalder, C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;47:276–7. https://doi.org/10.1002/1531-8249(200002)47:2<276::aid-ana28>3.0.co;2-1.10.1002/1531-8249(200002)47:2<276::AID-ANA28>3.0.CO;2-1Search in Google Scholar
© 2022 Walter de Gruyter GmbH, Berlin/Boston